Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28210980 | 0.83 | BRD9 (0.39) | CYP17A1BRD9PPARGELANECTRB1 | |
| SCHEMBL3988441 | 0.82 | BRD9 (0.38) | CYP17A1BRD9ELANECTRB1CA12 | |
| SCHEMBL28740739 | 0.78 | ELANE (0.41) | METAP2CYP17A1BRD9ELANECTRB1 | |
| SCHEMBL6181078 | 0.77 | RXFP1 (0.38) | CYP17A1CNR2BRD9CYP1A2CYP2C9 | |
| SCHEMBL23093071 | 0.77 | METAP2 (0.42) | METAP2CNR2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20670519 | 0.77 | CYP17A1 (0.41) | CYP17A1CNR2PPARGPPARACYP1A2 | |
| SCHEMBL23000604 | 0.77 | HDAC1 (0.38) | CYP17A1CNR2BRD9ELANECTRB1 | |
| SCHEMBL15440643 | 0.76 | CA12 (0.47) | CNR2CYP1A2CYP2C9CYP2C19KCNQ4 | |
| SCHEMBL6395566 | 0.76 | CISD2 (0.40) | CYP17A1BRD9ELANECTRB1CA12 | |
| SCHEMBL3984461 | 0.75 | KDM4E (0.51) | BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885CYP17A1 4561/4885CNR2 2407/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885CYP17A1 4561/4885CNR2 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.